Efficacy and safety of Sofosbuvir plus Daclatasvir or Ravidasvir in patients with COVID-19.
Conducted by: Sherif Abbas et al. J Med Virol.2021.
Read more...
Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection conducted by the WHO mentioning Ravidasvir in the following section:
“Other DAA regimens Additional evidence being generated may indicate in the future that other DAA regimens (e.g. sofosbuvir/ravidasvir) are pangenotypic or that existing pangenotypic DAA regimens can be used in more populations (e.g. children and adolescents <18 years of age)”
Read more...
Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients with Chronic Hepatitis C Infection.
Conducted by: Yakoot M1, El-Shabrawi MH2, AbdElgawad MM3, Mahfouz AA3, Helmy S4, Abdo AM5, El-Khayat HR6.
Read more...
Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4.
Conducted by: Esmat G1, Elbaz T2, El Raziky M3, Gomaa A4, Abouelkhair M3, Gamal El Deen H1, Sabry A4, Ashour M3, Allam N4, Abdel-Hamid M5, Nada O6, Helmy S7, Abdel-Maguid H7, Colonno R8, Brown N8, Ruby E8, Vig P8, Waked I9. F
Read more...
Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals.Hill
Conducted by: A1, Tahat L2, Mohammed MK3, Tayyem RF3, Khwairakpam G4, Nath S5, Freeman J6, Benbitour I7, Helmy S8.
Read more...
Shortened 8 Weeks Course of Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients, With Chronic Hepatitis C Infection.
Conducted by: El-Shabrawi MH1, Abdo AM2, El-Khayat HR3, Yakoot M4.
Read more...
Response Tailored Protocol Versus the Fixed 12Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial.
Conducted by: Yakoot M1, Abdo AM2, Abdel-Rehim S2, Helmy S3.
Read more...
Very rapid virologic response and early HCV response kinetics, as quick measures to compare efficacy and guide a personalized response-guided therapy.
Conducted by: Yakoot M1, Abdo AM2, Yousry A3, Helmy S4.
Read more...
The very-rapid and the ultra-rapid virologic response to two treatment options in patients with chronic hepatitis C: an interim report of a prospective randomized comparative effectiveness study.
Conducted by: Yakoot M1, Abdo AM2, Yousry A3, Helmy S4.
Read more...
Effect of a topical copper indomethacin gel on inflammatory parameters in a rat model of osteoarthritis.
Conducted by: Yassin NZ1, El-Shenawy SM1, Abdel-Rahman RF1, Yakoot M2, Hassan M3, Helmy S4.
Read more...
Clinical efficacy of Spasmofen® suppository in the emergency treatment of renal colic: a randomized, double-blind, double-dummy comparative trial.
Conducted by: Yakoot M1, Salem A2, Yousef S2, Helmy S3.
Read more...
Effect of Memo®, a natural formula combination, on Mini-Mental State Examination scores in patients with mild cognitive impairment.
Conducted by: Yakoot M1, Salem A, Helmy S.
Read more...
Pilot study of the efficacy and safety of lettuce seed oil in patients with sleep disorders.
Conducted by: Yakoot M1, Helmy S, Fawal K.
Read more...
Clinical efficacy of farcosolvin syrup (ambroxol-theophylline-guaiphenesin mixture) in the treatment of acute exacerbation of chronic bronchitis.
Conducted by: Yakoot M1, Salem A, Omar AM.
Read more...
Safety and efficacy of a new honey ointment on diabetic foot ulcers: a prospective pilot study.
Conducted by: Abdelatif M1, Yakoot M, Etmaan M.
Read more...
Ravidasvir-Sofosbuvir Combo Shows Promise in Chronic Hep C Infection.
Conducted by:Matthew Phelan
Read more...
Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial.
Conducted by: MD Isabelle Andrieux-Meyer, MRCP Soek-Siam Tan, MD Sombat Thanprasertsuk et al.
Read more...